This is a phase I study to establish the safety and feasibility of lentiviral transduced CAR T cell products in patients with mesothelin expressing breast cancer. This study will be initiated as a single cohort (described below), however the adaptive design will allow for additional disease indications and other investigational CAR T cell products to be explored as separate cohorts under this protocol in the future.
Phase 1 - Safety and Proof of Concept